Archive for July, 2011
ANDA Filing Aganist Ofirmev Is Not Unduly Concerning (CADX, $9.25)
Investment Opinion I believe that the Ofirmev approval is a game changer that can propel Cadence into a successful, medium tier, earnings driven bio-pharmaceutical company. While I am recommending purchase of Cadence, I think that it important for investors to understand the risks and uncertainties of the investment outlook. This note discusses the patent challenge […]
Provenge Receives Final CMS Reimbursement Approval (DNDN, $41.40)
CMS Approval Removes Investor Concern CMS issued its final national coverage decision on Provenge yesterday and confirmed the preliminary decision that specifically states that treatment with Provenge is reasonable and necessary. This assures provider reimbursement for Medicare beneficiaries when Provenge is used on-label to treat asymptomatic and minimally symptomatic castrate resistant prostate cancer patients. This […]
Yervoy Was A Star at American Society of Oncology: Commercial Potential Is Enormous (BMY, $29.15)
Investment Overview I have previously written about Bristol-Myers Squibb (BMY) as having possibly the best pipeline among the major pharmaceutical firms. Despite the new product outlook, I estimate that the loss of sales from products coming off patent will cause overall sales to decrease from $20.4 billion in 2011 to $16.6 billion in 2013. The […]